Last checked at 
FRANKFURT, April 15 (Reuters) - German biotech firm CureVac
said it would start testing its COVID-19 vaccine on
adolescents as young as 12 at the end of the month, as it gets
ready to publish initial efficacy results for adults in the
second quarter.
CureVac said it would initially enrol about 40 adolescent
participants aged 12 to 17 in Peru and Panama, the first stage
of a broader study in this age group.
Its ongoing pivotal Phase 2b/3 study known as Herald and
initiated in December has completed recruitment with over 40,000
adult participants in Europe and Latin America, the company said
on Thursday.
(Reporting by Ludwig Burger, editing by Kirsti Knolle)
